DocMorris AG (XSWX:DOCM) ROE %: -30.01% (As of Jun. 2025)


XSWX:DOCM DocMorris AG XSWX:DOCM
65 GF Score
Price CHF7.92
GF Value CHF10.53
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is DocMorris AG ROE %?

DocMorris AG XSWX:DOCM +0.06% 65 ROE % is -30.01% as of Jun. 2025. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.53 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 628 Healthcare Providers & Services companies, DocMorris AG ranks worse than 85.03% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DocMorris AG's annualized net income for the quarter that ended in Jun. 2025 was CHF-123 Mil. DocMorris AG's average Total Stockholders Equity over the quarter that ended in Jun. 2025 was CHF410 Mil. Therefore, DocMorris AG's annualized ROE % for the quarter that ended in Jun. 2025 was -30.01%.

The historical rank and industry rank for DocMorris AG's ROE % or its related term are showing as below:

XSWX:DOCM' s ROE % Range Over the Past 10 Years
Min: -44.41   Med: -16.34   Max: 21.06
Current: -29.72

During the past 13 years, DocMorris AG's highest ROE % was 21.06%. The lowest was -44.41%. And the median was -16.34%.

XSWX:DOCM's ROE % is ranked worse than
85.03% of 628 companies
in the Healthcare Providers & Services industry
Industry Median: 5.72 vs XSWX:DOCM: -29.72

DocMorris AG  (XSWX:DOCM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2025 )
=Net Income/Total Stockholders Equity
=-123.11/410.2295
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-123.11 / 1082.946)*(1082.946 / 842.7865)*(842.7865 / 410.2295)
=Net Margin %*Asset Turnover*Equity Multiplier
=-11.37 %*1.285*2.0544
=ROA %*Equity Multiplier
=-14.61 %*2.0544
=-30.01 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2025 )
=Net Income/Total Stockholders Equity
=-123.11/410.2295
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-123.11 / -121.51) * (-121.51 / -100.02) * (-100.02 / 1082.946) * (1082.946 / 842.7865) * (842.7865 / 410.2295)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0132 * 1.2149 * -9.24 % * 1.285 * 2.0544
=-30.01 %

Note: The net income data used here is two times the semi-annual (Jun. 2025) net income data. The Revenue data used here is two times the semi-annual (Jun. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


DocMorris AG ROE % Related Terms


DocMorris AG ROE % Historical Data

* Premium members only.

The historical data trend for DocMorris AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DocMorris AG ROE % Chart

DocMorris AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.95 -44.41 -40.95 21.06 -25.24

DocMorris AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.04 -25.67 -18.28 -32.07 -30.01

DocMorris AG ROE % Competitor Comparison

For the Pharmaceutical Retailers subindustry, DocMorris AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DocMorris AG ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's ROE % distribution charts can be found below:

* The bar in red indicates where DocMorris AG's ROE % falls into.


XSWX:DOCM
65GF Score
DocMorris AG XSWX:DOCM
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DocMorris AG ROE % Calculation

DocMorris AG's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-97.253/( (430.532+340.114)/ 2 )
=-97.253/385.323
=-25.24 %

DocMorris AG's annualized ROE % for the quarter that ended in Jun. 2025 is calculated as

ROE %=Net Income (Q: Jun. 2025 )/( (Total Stockholders Equity (Q: Dec. 2024 )+Total Stockholders Equity (Q: Jun. 2025 ))/ count )
=-123.11/( (340.114+480.345)/ 2 )
=-123.11/410.2295
=-30.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -30.01% mean?
DocMorris AG (XSWX:DOCM) has a ROE % of -30.01% as of Jun. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on DocMorris AG and its competitors. According to the industry distribution chart, DocMorris AG ranks #534 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 85%.
Is DocMorris AG's ROE % too high?
DocMorris AG's current ROE % is -30.01%. Based on the distribution chart, DocMorris AG ranks #534 out of 628 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #534 out of 628 companies for ROE %. This places DocMorris AG in the lower half of its industry. The industry median ROE % is 5.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current ROE % is -30.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.53, compared to a current price of CHF7.92 — trading 24.8% below its estimated fair value. The current ROE % is -30.01%. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current ROE % is -30.01% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?

Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued. The current stock price of CHF7.92 is trading 24.8% below its estimated GF Value™ of CHF10.53. GuruFocus considers DocMorris AG to be Modestly Undervalued.

Key valuation signals for XSWX:DOCM:

  • ROE %: -30.01%
  • GF Value™: CHF10.53 vs. price of CHF7.92 (24.8% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DocMorris AG Business Description

Other Exchanges DOCMz:UK0RRB:UKZRE:Germany
Address Walzmuhlestrasse 49, Frauenfeld, CHE, 8500
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score

Get the complete analysis for XSWX:DOCM

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.92
Price
CHF10.53
GF Value